Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.

Cheson BD.

J Clin Oncol. 2010 Jul 20;28(21):3525-30. doi: 10.1200/JCO.2010.27.9836. Epub 2010 May 10. Review.

PMID:
20458041
2.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
3.

rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.

Ge X, Wu L, Hu W, Fernandes S, Wang C, Li X, Brown JR, Qin X.

Clin Cancer Res. 2011 Nov 1;17(21):6702-11. doi: 10.1158/1078-0432.CCR-11-0647. Epub 2011 Sep 14.

4.

Ofatumumab, a human anti-CD20 monoclonal antibody.

Osterborg A.

Expert Opin Biol Ther. 2010 Mar;10(3):439-49. doi: 10.1517/14712590903586239. Review.

PMID:
20109133
5.

The future of CD20 monoclonal antibody therapy in B-cell malignancies.

Czuczman MS, Gregory SA.

Leuk Lymphoma. 2010 Jun;51(6):983-94. doi: 10.3109/10428191003717746. Review.

PMID:
20367564
6.

Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia.

O'Brien S, Osterborg A.

Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):361-8. doi: 10.3816/CLML.2010.n.069. Review.

PMID:
21030349
7.

Ofatumumab for the treatment of chronic lymphocytic leukemia.

Grosicki S.

Expert Rev Hematol. 2015 Jun;8(3):265-72. doi: 10.1586/17474086.2015.1037736. Epub 2015 Apr 16. Review.

PMID:
25882470
8.

Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.

Barth MJ, Czuczman MS.

Future Oncol. 2013 Dec;9(12):1829-39. doi: 10.2217/fon.13.219.

PMID:
24295413
9.

Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.

Reagan JL, Castillo JJ.

Expert Rev Anticancer Ther. 2011 Feb;11(2):151-60. doi: 10.1586/era.10.223. Review.

PMID:
21342032
10.

Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.

Gupta IV, Jewell RC.

Ann N Y Acad Sci. 2012 Aug;1263:43-56. doi: 10.1111/j.1749-6632.2012.06661.x. Epub 2012 Jul 25. Review.

PMID:
22830942
11.

New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.

Robak T, Robak E.

BioDrugs. 2011 Feb 1;25(1):13-25. doi: 10.2165/11539590-000000000-00000. Review.

PMID:
21090841
12.

Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.

Kobayashi H, Matsunaga Y, Uchiyama Y, Nagura K, Komatsu Y.

Cancer Med. 2013 Apr;2(2):130-43. doi: 10.1002/cam4.60. Epub 2013 Feb 20.

13.

Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.

Jain P, O'Brien S.

Expert Opin Biol Ther. 2013 Feb;13(2):169-82. doi: 10.1517/14712598.2012.735655. Epub 2012 Dec 21. Review.

PMID:
23256681
14.

Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.

Nightingale G.

Ann Pharmacother. 2011 Oct;45(10):1248-55. doi: 10.1345/aph.1P780. Epub 2011 Sep 6. Review.

PMID:
21896924
15.

Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.

Klitgaard JL, Koefoed K, Geisler C, Gadeberg OV, Frank DA, Petersen J, Jurlander J, Pedersen MW.

Br J Haematol. 2013 Oct;163(2):182-93. doi: 10.1111/bjh.12503. Epub 2013 Aug 8.

PMID:
23927424
16.
17.

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.

Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS.

Br J Haematol. 2012 Feb;156(4):490-8. doi: 10.1111/j.1365-2141.2011.08966.x. Epub 2011 Dec 9.

PMID:
22150234
18.

Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.

Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC.

MAbs. 2014 May-Jun;6(3):749-55. doi: 10.4161/mabs.28282. Epub 2014 Mar 4.

19.

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.

Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, Hoelzer D, Mitrou PS, Weidmann E.

Haematologica. 2002 Jan;87(1):33-43.

20.

Ofatumumab in the treatment of chronic lymphocytic leukemia.

Tsimberidou AM.

Drugs Today (Barc). 2010 Jul;46(7):451-61. doi: 10.1358/dot.2010.46.7.1497416. Review.

PMID:
20683500

Supplemental Content

Support Center